Pharmacokinetics of linezolid treatment using intravenous and oral administrations in extremely premature infants

European Journal of Clinical Pharmacology
Mélanie SicardChristèle Gras-Le Guen

Abstract

Vancomycin is the usual antibiotic treatment in coagulase-negative staphylococcus sepsis in premature infants but causes renal toxicity. As linezolid is effective in Gram-positive cocci infection, and devoid of renal side-effects, it has been used in Nantes neonatal intensive care units and linezolid plasma concentrations were monitored. The aims of this study are to report data on linezolid concentrations in premature infants, describe clinical and bacteriological evolution during treatment, and determine potential side effects. A retrospective observational study of premature infants treated with linezolid in Nantes Hospital from January 2008 through November 2011 was conducted. Linezolid plasma concentrations, possible side effects due to linezolid, and clinical response to linezolid treatment were collected from folder review. Twenty-four linezolid plasma concentrations were monitored in 16 premature patients, at steady state for continuous intravenous administration or 7 ± 1.5 h after last oral administration. Except for one case, linezolid plasma concentrations were ≥minimal inhibition concentration (MIC) for linezolid for both parenteral and oral administrations. We observed three cases of thrombocytopenia, two of leukop...Continue Reading

References

Dec 3, 1998·Antimicrobial Agents and Chemotherapy·S M SwaneyD L Shinabarger
Aug 13, 2003·The Pediatric Infectious Disease Journal·Sheldon L KaplanUNKNOWN Linezolid Pediatric Study Group
Oct 2, 2003·The Pediatric Infectious Disease Journal·Gail L JungbluthNancy K Hopkins
Oct 2, 2003·The Pediatric Infectious Disease Journal·H Cody MeissnerJon B Bruss
Oct 2, 2003·The Pediatric Infectious Disease Journal·Lisa SaimanJon B Bruss
Oct 31, 2003·Clinical Pharmacology and Therapeutics·Gregory L KearnsUNKNOWN Pediatric Pharmacology Research Unit Network
Nov 12, 2005·The Pediatric Infectious Disease Journal·Daniel A C FrattarelliJacob V Aranda
Oct 12, 2007·Expert Opinion on Pharmacotherapy·Konstantinos Z VardakasMatthew E Falagas
Dec 3, 2009·The Pediatric Infectious Disease Journal·Michael Cohen-WolkowiezP Brian Smith
Mar 9, 2011·Pediatrics·Isabelle GuellecUNKNOWN EPIPAGE Study Group
Aug 20, 2011·The Pediatric Infectious Disease Journal·Erik SuMarian G Michaels

❮ Previous
Next ❯

Citations

Mar 17, 2016·Expert Opinion on Drug Metabolism & Toxicology·Dario CattaneoMichael Neely
Feb 25, 2020·The Pediatric Infectious Disease Journal·Mélanie SicardJulie Autmizguine
Sep 25, 2020·Antimicrobial Resistance and Infection Control·Lucie MatratMarine Butin
Jun 27, 2019·The Journal of Antimicrobial Chemotherapy·Fleur M KeijGerdien A Tramper-Stranders
Mar 18, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hideo KatoHiroshige Mikamo

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.